Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tacrolimus Clear all
Completed Phase 1Phase 2 Interventional

Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients

NCT00403416
View directory record Official record
Conditions
Kidney Transplantation
Interventions
AEB071, Mycophenolic Acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
San Francisco, California • Cleveland, Ohio • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 4 Interventional

A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Patients

NCT00650468
View directory record Official record
Conditions
Renal Transplantation
Interventions
tacrolimus, CellCept, steroids (methylprednisone or prednisone)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
29
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Jul 23, 2026, 4:04 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

NCT04877288
View directory record Official record
Conditions
Renal Allograft Recipients
Interventions
Belatacept, Tacrolimus, Cyclosporine A, Mycophenolate Mofetil, Enteric Coated Mycophenolate Sodium, Corticosteroids
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

NCT01534143
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
pharmacological study, tacrolimus, sirolimus, anti-thymocyte globulin, fludarabine phosphate, busulfan, bortezomib, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis
Other · Drug · Biological + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

NCT03480360
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
Interventions
Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
Drug · Radiation · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia

NCT00578266
View directory record Official record
Conditions
Anemia, Aplastic
Interventions
Cyclophosphamide,Campath IH and TBI
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT00031824
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
cyclosporine, hydroxychloroquine, prednisone, tacrolimus
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

NCT00796562
View directory record Official record
Conditions
MDS, Leukemias, Lymphomas
Interventions
Busulfan, Cyclophosphamide, Total body irradiation
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

NCT00296296
View directory record Official record
Conditions
Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 23, 2026, 4:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin, mycophenolate mofetil, mycophenolate sodium, methylprednisolone, prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients

NCT03591380
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belimumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 23, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

NCT05027945
View directory record Official record
Conditions
Immunodeficiency, Hematopoietic Stem Cell Transplantation
Interventions
Allogeneic HSCT, Busulfan test dose, Mycophenolate mofetil (MMF), Tacrolimus, Busulfan, Total Body Irradiation (TBI), Fludarabine, Cyclophosphamide (CY), Post-Transplant Cyclophosphamide (PTCY)
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients

NCT03020589
View directory record Official record
Conditions
Renal Transplant
Interventions
Tacrolimus
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jul 23, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

NCT00920972
View directory record Official record
Conditions
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 20 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

NCT01888432
View directory record Official record
Conditions
Liver Transplantation
Interventions
Everolimus + reduced tacrolimus, Standard tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2019 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

NCT00275509
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Thymoglobulin, Daclizumab, Plasmapheresis, Mycophenolate mofetil, Tacrolimus, Dexamethasone, Prednisone, Cytogam
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Jul 23, 2026, 4:04 PM EDT
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional

Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns

NCT05856994
View directory record Official record
Conditions
Burn Injury
Interventions
Tacrolimus ointment
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids

NCT00170053
View directory record Official record
Conditions
Kidney Diseases
Interventions
Sirolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 23, 2026, 4:04 PM EDT